Press releases

Release issued 21st February 2006

York, UK—Partneringreview™ 2006 (http://pharmalicensing.com/desk) provides an overview of deals from the whole of 2005 from pharmaceutical and biotechnology companies, and is a comprehensive summary of the year's deal announcements in a clear and accessible printable format.

This second edition sees innovative additions including a fuller coverage of Japanese deals and alliances, courtesy of JCN; a merger and acquisition chapter; and a brand new financings volume detailing investment information in the form of grants/awards, private financings, loans, IPO and public placements from investors.

In the past year, the Partneringdesk team has collected over 2,600 new deals and has extended the database with over 1,100 financings. The report supports active partner identification, highlighting outstanding therapy areas and types of deal-making activity, and tracks the amount and type of financing investment by lead investors.

The report is subdivided into six volumes: company deal index, therapy area, financings, stage of development, deal type, and industry sector. In each volume, subdivision into chapters provides a standalone review of the specific area, analyzing deals announced by company, industry focus, therapy focus and development stage. The report also includes a review of deal making in 2005, and new volume-specific analytical introductions with graphs. Every deal entry includes financial information where disclosed, such as headline values, upfront and milestone payments. Partneringreview 2006 is available as the full report, by volume, or by chapter.

In 2005, deals across the 14 main therapeutic areas showed the same or a slight increase in therapy area activity compared with 2004, with the exception of the blood/lymphatic system, which showed a more pronounced decrease in activity compared with 2004. The two leading therapy areas are still oncology and infectious disease. 2005 was a busy year for research and development collaborations, overall up by almost 30% from the previous year. According to Partneringreview 2006, the top 50 biopharmaceutical company, Novartis, was the most active in deal making in the form of collaborative R&D and marketing/promotion with 26 and 23 deals respectively. GlaxoSmithKline was most active in pursuing licensing agreements with 23 deals. The National Institutes of Health announced around 45 grants, a figure that increases to over 70 if individual institutes are included.

"Partneringreview, put together by our expert team, provides readers with an excellent value overview of the partnering strategies within the pharmaceutical and biotechnology industry", said Suzanne Elvidge, Head of Publishing. "Because it can be broken down in so many ways, this highly flexible report can help companies to identify active partners, track competitor activity, benchmark deals and compare the finances of different deal types, aiding dealmaking at all stages and in all areas."

For more information on Partneringreview or other products from Partneringdesk, go to http://pharmalicensing.com/desk, or contact the Partneringdesk team on tel: +44 1904 520460 or email: partneringdesk@pharmalicensing.com.

Pharmalicensing (http://pharmalicensing.com), based in York, UK, is the world's number one partnering resource for the biopharmaceutical industry. Pharmalicensing provides pharmaceutical companies with a wide-ranging forum to exchange partnering wants and needs with a global audience.

Bridgehead International is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain, through three divisions: Bridgehead Consulting; Healthcare Education Services; and Pharmalicensing.

Contact: Suzanne Elvidge, Head of Publishing (suzanne.elvidge@bridgehead.com; Tel +44 1904 520464)

(20th May 2013) Pharmalicensing and Bionow sign strategic marketing and member benefit agreement

(5th January 2012) Innovaro Announces Successful Sale of the Waycool Portfolio of Patents by CUI Global, Inc.

(28th January 2010) New collaboration presents big opportunities for UK SMEs

(14th January 2010) UTEK Pharmalicensing.com Announces New Pricing Model: Pay-per-Click to Expand Listed Opportunities, Extend Reach and Remove Market Barriers

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.